Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:12 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,546 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Girls, alone Clear all
Completed No phase listed Observational Results available

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

NCT05012644
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib + aromatase inhibitor, Aromatase inhibitor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.

NCT06473519
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSVpreF MDV, RSVpreF SDV
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
6
States / cities
South Miami, Florida • Stockbridge, Georgia • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

NCT02300363
View directory record Official record
Conditions
Healthy
Interventions
Treatment A (rosuvastatin), Treatment B (LX4211), Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Nov 1, 2026, 5:12 AM EST
Recruiting Phase 3 Interventional

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
Interventions
olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
33
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

NCT04663464
View directory record Official record
Conditions
Healthy Volunteers
Interventions
abaloparatide-sMTS, abaloparatide-SC
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Nov 1, 2026, 5:12 AM EST
Recruiting Not applicable Interventional

Heart Disease of the Small Arteries in Women and Men

NCT00573027
View directory record Official record
Conditions
Heart Disease
Interventions
noninvasive tests
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2040
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Nov 1, 2026, 5:12 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Dried Cabernet Grapes and Cardiovascular Risk Markers

NCT03065166
View directory record Official record
Conditions
Healthy, Postmenopausal Women
Interventions
Raisin Treatment, Bagel Control
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

NCT02237729
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06410293, Adalimumab-US, Adalimumab-EU
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
362 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Coral Gables, Florida • Jacksonville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Nov 1, 2026, 5:12 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Osteoclast Inhibition and Bone Formation

NCT02554695
View directory record Official record
Conditions
Bone Loss, Aging
Interventions
placebo, denosumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 80 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional

Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration

NCT05008341
View directory record Official record
Conditions
Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum
Interventions
Solriamfetol 150 mg Oral Tablet
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Nov 1, 2026, 5:12 AM EST
Active, not recruiting Phase 1 Interventional

Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

NCT05223829
View directory record Official record
Conditions
PTSD, Alcohol Use Disorder
Interventions
Brexanolone
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 1, 2026, 5:12 AM EST
Active, not recruiting Phase 2 Interventional

A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer

NCT04298086
View directory record Official record
Conditions
Breast Cancer, Primary Hormone Receptor Positive Breast Cancer
Interventions
Exercise Treatment, Plant-Based Diet, Physical activity, Nutrition counseling, Replication Exercise Test
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

NCT00881062
View directory record Official record
Conditions
ABSORPTION, METABOLISM, EXCRETION
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)

NCT03608241
View directory record Official record
Conditions
Healthy Females
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonogestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Nov 1, 2026, 5:12 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

GSK706769 A First Time in Human Study For Males and Females

NCT00539201
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK706769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 3 Interventional Results available

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

NCT00048061
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate [Bonviva/Boniva], Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
20
States / cities
Irvine, California • Loma Linda, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Nov 1, 2026, 5:12 AM EST
Withdrawn No phase listed Observational

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

NCT06058728
View directory record Official record
Conditions
Uterine Fibroids (UF)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional

Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

NCT05892757
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Atogepant, Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Springfield, Missouri • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

NCT01237067
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer
Interventions
Carboplatin, Olaparib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

NCT00648154
View directory record Official record
Conditions
Healthy
Interventions
Letrozole Tablets 2.5 mg, Femara® Tablets 2.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects

NCT03302845
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Omeprazole 40 MG, Famotidine 40 mg, Telotristat ethyl 250 mg
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 2 Interventional Results available

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

NCT03007979
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
Interventions
Palbociclib, Letrozole, Fulvestrant, Optional research biopsy, Goserelin, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Nov 1, 2026, 5:12 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

NCT06381466
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
AZD0233, AZD0233 Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Nov 1, 2026, 5:12 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants

NCT01656018
View directory record Official record
Conditions
Healthy
Interventions
TMC278, Long acting (LA)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Nov 1, 2026, 5:12 AM EST